Reasons to Choose Taiwan UBI Asia in Partnership with UBI Chang Yi Wang, PhD Founder, UBI Chairperson, UBI Asia

Core Technology UBI / UBI Asia Cytotoxic T Neutralization Lymphocyte Functional Antigenics UBI / UBI Asia Molecular Design of Functional Antigens Adjuvant & Formulation Technologies UBITh ® Technology Synthetic Peptide Antigenic Combinatorial Library Cytotoxic T Lymphocyte Neutralization Antibodies Antibody Deimmunization Immunodiagnostics Therapeutic Monoclonal Antibodies Vaccines and Immunotherapeutics

Product Portfolios Vaccines & Immunotherapeutics Functional Antigenics LHRH Vaccine as Prostate Cancer Therapeutic HIV/AIDS Vaccine & Therapeutic Allergy Therapeutic Alzheimer Disease SARS Vaccine & Diagnostics Canine Allergy Therapeutic FMDV Vaccine & Diagnostics LHRH Vaccine for Boar Taint Removal & Growth Promotion as Pet Contraceptive Functional Antigenics Animal Health Products Human Health Products

Business partners and Product Development Sponsors of UBI Division of AIDS, NIAID, NIH, USA [HIV Immunotherapeutics] NIAID, NIH, USA [Allergy Immunotherapeutic] NCI, NIH, USA [Prostate Cancer Immunotherapeutic] Baxter, USA BioMerieux (Lyon, France), formerly Organon Teknika of Akzo Nobel (Boxtel, Netherlands) Merial (Lyon, France) (JV of Merck and Aventis, largest animal health company in the world) The United Laboratories (Zhuhai, China) China Animal Husbandry Industry Corp. (Beijing, China)

Synergy: Traditional Pharma / Innovative Bio Peptide Pilot Plant Protein Drug Pilot Plant Biologics Manufacture Plant cGMP Roche GSK BioPharmaceutics Foundation in Taiwan Toll Manufacture Pharmaceutics Foundation in Taiwan Compliance with FDA International BioPharmaceutics Company Specialty Injectables

Business Model rowth Survival Synergy cGMP Pharmaceutical Plants Pharma / Bio UBI / UBI Asia rowth

Survival: Conservative Nurtures High Risk UBI 技術轉移 UBI Asia 技術承接 & 產品創新研發 cGMP Manufacture Acquire Roche & GSK cGMP plants: Chemical drugs, Biologics 1999 2002 Innovative R & D Peptide based: Vaccine & diagnostics Protein based: Therapeutic monoclonal antibodies

From Genomics to Products Innovation Through Design UBI Asia FMDV Vaccine: Ko-T Con ® 口蹄安 FMDV Diagnostics From Genomics to Products Innovation Through Design

Complete Replacement of Traditional Vaccines The Vision: Complete Replacement of Traditional Vaccines within 5 Years !!

From Genomics to Products Innovation Through Design UBI Asia UBITh® LHRH Immunotherapeutic Boar Taint Removal Vaccine: Bota Con ® 寶特康 Pet Contraceptive Vaccine Human Prostate Cancer Therapeutic From Genomics to Products Innovation Through Design

BotaCon ®寶特康: An Immunotherapeutic to eliminate Boar Taint and promote pig growth and

Cattle

UBI Asia Therapeutic Monoclonal Antibodies

Monoclonal Antibody Engineering Monoclonal Antibody Humanization (Murine Ab to Human Ab) Hybridoma, Cesar Milstein & Georges Kohler Chimeric mAb, Genentech Fc Fv CDR grafting, PDL 1975 1994 1986 OKT3, 1986, 55 M USD RePro, 1994, 447 M USD Rituxan, 1997, 298 M USD Deimmunization, Biovation 1998 Identification of T cell and B cell antigenic epitopes in Variable regions

Well-Characterized Monoclonal Antibody (B4) directed against HIV receptor complex for treatment of HARRT resistant AIDS patients through entry inhibition

UBI Asia provides services to and collaborates with multiple commercial and research institutes 先導工廠 聯亞研發中心 產程發展 & 原料藥生產 UBI Asia R & D 聯亞生產中心 聯亞cGMP廠 西藥 & 生技藥品 劑型生產 配方研發 臨床試驗 產品登記

Vision: Designer Immunological Products UBI國際 臨床&事業 中心 UBI Asia 研發&生產 for the treatment, prevention, and diagnosis of globally significant diseases 中國大陸 歐洲 東南亞 日本、韓國 UBI國際 臨床&事業 中心 美國、美洲 台 灣 UBI Asia 研發&生產

Synergy: UBI Asia / UBI MOEA UBI Asia NIH UBI R & D Center Basic Research Process Development Field & Clinical Trials UBI

Reasons to Choose Taiwan UBI Asia in Partnership with UBI Taiwan government with policies to promote biotechnology Taiwan has diligent, entrepreneurial and well-educated human resources Operations can be cost effective when compared with the west Easy access to fast breaking first hand business information Access to huge China market due to similarity in language and cultural background Training and testing ground for worldmarket due to its extensive connections to the western world

Join us, and Welcome to Taiwan!